Navigation Links
LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic,Protection Against Influenza Challenge With Virus-Like Particle,Immunization

BOZEMAN, Mont., May 01, 2007 /PRNewswire/ -- LigoCyte Pharmaceuticals presented preclinical data today showing that immunization with their influenza virus-like particles (VLPs) induced heterosubtypic protection in a virus challenge study. The company's data were presented by Dr. Joel Haynes, LigoCyte's senior director of vaccine development, at the Tenth Annual Conference on Vaccine Research sponsored by the National Foundation of Infectious Diseases in Baltimore.

The current influenza vaccination strategy involves immunization against hemagglutinin antigens that undergo continuous alteration in circulating influenza virus. Because the annual vaccines have to be manufactured in advance of influenza outbreaks, the unexpected emergence of a new or drifted subtype may result in a substantial reduction in protection.

LigoCyte's data show that immunization with their unique influenza H1N1-VLP formulation resulted in 100% protection against both H1N1 and H3N2 influenza challenge in preclinical studies. LigoCyte has also produced influenza VLPs carrying H3N2 and H5N1 antigens. H5N1 is the avian flu subtype that is currently circulating in bird populations and causing sporadic infections and death in humans.

"There is a great need for a universal influenza vaccine that simplifies manufacturing and delivery while enhancing protection against multiple viral subtypes," said Dr. Robert Bargatze, LigoCyte's chief scientific officer.

About LigoCyte:

LigoCyte, established in 1998, is developing a new generation of vaccines and monoclonal antibody therapeutics for the prevention and treatment of infectious diseases and inflammation. The company's investigational Norovirus vaccine for the prevention of acute gastroenteritis is currently in Phase I clinical studies. LigoCyte is advancing its other proprietary products into human clinical testing, positioning the company for continued growth an
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/23/2008)...Company Focused on IND-Enabling Work with Protein ...athway of Complement System, CAMBRIDGE, Mass., Ju...day announced it has initiated a corporate growth ..., as chief executive officer and the,establishment...ker succeeds,Woodruff Emlen, M.D., a co-founder of...
(Date:7/22/2008)...- Strong efficacy results from a multi-center 293-...com , Toronto Stock Exchange Symbol: CYT, MONTRE...echnologies,Inc., the global leader in cryotherapy...unced that results previously presented from three...roduct, Arctic Front(R),were published earlier to...
(Date:7/22/2008)...Latest awards under Therapeutics Development Initi...rations to 23; next deadline January 20,2009, NE... of its mission to,speed delivery of transformativ...he Michael J. Fox Foundation for Parkinson,s Resea...ix industry research teams. The awards,were grante...
(Date:7/22/2008)...tudy Demonstrates Feasibility and Efficacy of Trea...y Liver Cancer, SAN FRANCISCO, and YONGIN-SI, Sou...San Francisco, CA and Ottawa, Ontario), and its So...day that novel findings from,a Phase I clinical tr...nstrated that the product was well-tolerated and r...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Psoriasis Study Showing Increased Risk of Death Underscores Need for More Research Group Says 8476 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 2MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 3Synthetech Earns National Recognition for Performance Improvement Program 2270 1Synthetech Earns National Recognition for Performance Improvement Program 2270 2Synthetech Earns National Recognition for Performance Improvement Program 2270 3Researchers hope to provide chronic fatigue syndrome answers 8470 1Researchers hope to provide chronic fatigue syndrome answers 8470 2
...History Highlighted in AACR Cancer Journal , AUSTI...Therapeutics, Inc. (NASDAQ:INGN) announced today t...nical benefit of its lead product,Advexin in a pat...,Li-Fraumeni Syndrome (LFS), a genetic disorder ch...r suppressor gene. This is the,first reported trea...
...LLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn,P...tical company,dedicated to the discovery, developm...s for cancer, central nervous system disorders,se...day announced,that Dr. John Marshall, Principal In...y,s lead cancer compound RX-0201 (Archexin),will ...
Other Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4
(Date:7/25/2008)...CESS, N.Y., July 25 /PRNewswire-USNewswire/ -- Ant...f Quality Officer and Vice President,of Strategic ...th Fund, a,national foundation committed to improv...ted the foundation,s Program on Health Care Qualit....newscom.com/cgi-bin/prnh/20080725/DC28791LOGO ),...
(Date:7/25/2008)...ON, Calif., July 25 /PRNewswire-FirstCall/ -- Thor...n device-based mechanical,circulatory support ther...,today announced that it will report its operating...hs of fiscal 2008 on Thursday, July 31., The comp...ancial,results and operating activities to all int...
(Date:7/25/2008)...A July 24, 2008 Being overweight or obese is not...ut is also a public health issue that impacts othe...ealth Services Research reveals that the extra Me...ple could place a significant financial burden on ...dollars across the entire current Medicare populat...
(Date:7/25/2008)...July 25 /PRNewswire/ -- BeaconEquity.com announces... news today., Investors can view all of the daily...nEquity.com/m , Today,s Trade Alerts include: DUS...ok Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMed ..., Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis Inc....
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3
...cern over the AIDS crisis ravaging sub-Saharan Afr...'s XIII International AIDS Conference, researchers...many consider to be the next big trouble spot--Ind...ffing, and if there's an enemy of India it's not P...
... high levels of cholesterol but low levels that ar... Low levels of Cholesterol maybe linked to depress...en with relatively low cholesterol levels were up ... severe depression. Edward Suarez, PhD from Duke ...
...uld get a second medical opinion if they are told ...id tumors that could become cancerous.//'It is ver...cerous,' said Dr. Nelson Teng, chief of gynecologi...ool of Medicine.Fibroids are benign growths in the...
... all of you who thought that one only uses cortico...that have come out in the recent years which are d...Using Tacrolimus, the agent which was devised for ...st symptomatic relief of patients. Eczema is a dev...
Other Medicine News:
Every so often a new product comes along that isn't a small step but a giant leap ahead of everything that has preceeded it. Such is the impact of the Fidelity IAB.
...the perfect partner for growing your business prac...e scalable to meet your needs now and in the years...r FD20 system supports mixed-use as well as dedica...ws you to add new applications and techniques such...
...on CFX series represents a breakthrough that makes...ty. Its revolutionary design integrates Quantum 64...ies and advanced software. In fact, Aquilion CFX ... shown a sensitivity of 88% and specificity of 91%...
...2000 represents a new non-invasive approach to the...stem rapidly induces mild hypothermia in those pat...ia or rapidly reduces temperature in febrile patie...aintains core body temperature in a range of 33C (...
Medicine Products: